Press Releases

Date Title and Summary Additional Formats
Toggle Summary Quotient Limited to Participate in the Jefferies Virtual Healthcare Conference
JERSEY, Channel Islands, May 26, 2020 (GLOBE NEWSWIRE) -- Quotient Limited  (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the Company will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 9:00 a.m. ET.
View HTML
Toggle Summary Quotient Limited to Report Fiscal Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call
JERSEY, Channel Islands , May 26, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal fourth quarter and full year ended March 31, 2020 will be released before market open on Tuesday, June 9, 2020 .
View HTML
Toggle Summary Quotient Limited and hVIVO Announce Partnership to Support Wide-Spread COVID-19 Antibody Testing in the UK
JERSEY, Channel Islands , May 11, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, headquartered in Eysins, Switzerland , and hVIVO, part of Open Orphan plc (LONDON:ORPH), today announced that the MosaiQ™ by Quotient system and MosaiQ COVID-19
View HTML
Toggle Summary Quotient Limited Announces CE Mark for its SARS-CoV-2 (COVID-19) Antibody Microarray
JERSEY, Channel Islands , May 01, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland , today announced that it has completed the process for declaring conformity to the essential requirements of the In
View HTML
Toggle Summary Quotient Limited Announces SARS-CoV-2 (COVID-19) Antibody Test Final Performance Data
JERSEY, Channel Islands , April 27, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland , today reported very strong final study performance data for its SARS-CoV-2 antibody test.
View HTML
Toggle Summary Quotient Limited Announces SARS-CoV-2 (COVID-19) Antibody Test Performance Update
JERSEY, Channel Islands , April 21, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland , today reported positive performance data for its SARS-CoV-2 antibody test.
View HTML
Toggle Summary Quotient Limited Announces the Completion of the SARS-CoV-2 Antibody Test Development
JERSEY, Channel Islands , April 06, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland , today announced the completion of the development phase of a microarray based SARS-CoV-2 (COVID-19) antibody test
View HTML
Toggle Summary Quotient Limited to Host Investor Information Conference Call and Live Webcast
JERSEY, Channel Islands, March 13, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland , today announced the Company will host an investor information conference call and live webcast on March 25, 2020
View HTML
Toggle Summary Quotient Limited Reports Concordance Data from Extended Serological Disease Screening Benchmark Study
JERSEY, Channel Islands , Feb. 24, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland , today reported positive concordance data for its MosaiQ™ multimodality multiplex Extended Serological Disease
View HTML
Toggle Summary Quotient Limited Announces CE Mark Approval for Initial Serological Disease Screening Microarray
JERSEY, Channel Islands , Feb. 14, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland , today announced that it has received the Conformité Européene (CE) Mark approval for the Initial Serological
View HTML